A Phase 1b, Open-Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety , Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination with the PARP Inhibitor BGB-290 in Subjects with Advanced Solid Tumors

  • Markman, Ben (Primary Chief Investigator (PCI))
  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA Reference Number: HREC/15/MH/334.
SSA Reference Number: SSA/15/MonH/208.
Monash Health HREC Ref: 15537X
Effective start/end date25/03/1924/03/24


  • clinical trial
  • phase 1 study
  • advanced solid tumor
  • treatment efficacy